Who makes GVB-2001-low dose?

GVB-2001-low dose is developed by IVIEW Therapeutics Inc..

What development phase is GVB-2001-low dose in?

GVB-2001-low dose is in Phase 1.

Last reviewed 2026-04-19 · How we verify

GVB-2001-low dose

IVIEW Therapeutics Inc. · Phase 1 active Small molecule

At a glance

Generic name	GVB-2001-low dose
Sponsor	IVIEW Therapeutics Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GVB-2001-low dose CI brief — competitive landscape report
GVB-2001-low dose updates RSS · CI watch RSS
IVIEW Therapeutics Inc. portfolio CI